Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

被引：33

作者：

Maria Diez, Jose ^{[1
]}

Romero, Carolina ^{[1
]}

Vergara-Alert, Julia ^{[2
]}

Bello-Perez, Melissa ^{[3
]}

Rodon, Jordi ^{[2
]}

Manuel Honrubia, Jose ^{[3
]}

Segales, Joaquim ^{[4
,5
]}

Sola, Isabel ^{[3
]}

Enjuanes, Luis ^{[3
]}

Gajardo, Rodrigo ^{[1
]}

机构：

[1] Grifols, Biosci Res & Dev, Barcelona, Spain

[2] IRTA UAB, Ctr Recerca Sanitat Anim CReSA, IRTA, Campus Univ Autonoma Barcelona UAB, Barcelona, Spain

[3] CNB CSIC, Dept Biol Mol & Celular, Lab Coronavirus, Madrid, Spain

[4] UAB, CReSA IRTA UAB, Campus Univ Autonoma Barcelona UAB, Barcelona, Spain

[5] Univ Autonoma Barcelona UAB, Fac Vet, Dept Sanitat & Anat Anim, Barcelona, Spain

来源：

IMMUNOTHERAPY | 2020年 / 12卷 / 17期

关键词：

COVID-19; cross-neutralization; intravenous immunoglobulin; MERS-CoV; SARS-CoV; SARS-CoV-2; RECEPTOR-BINDING DOMAIN; SPIKE GLYCOPROTEIN; SARS CORONAVIRUS; ANTIBODIES; REACTIVITY; COVID-19; SERA;

D O I：

10.2217/imt-2020-0220

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background:Cross-reactivity against human coronaviruses with Flebogamma(R)DIF and Gamunex(R)-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).Materials & methods:Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods.Results:All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV.Conclusion:The tested IVIG contain antibodies with significantin vitrocross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.

引用

页码：1247 / 1255

页数：9

共 50 条

[1] Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto
Young-Jun Park
Martina Beltramello
Alexandra C. Walls
M. Alejandra Tortorici
Siro Bianchi
Stefano Jaconi
Katja Culap
Fabrizia Zatta
Anna De Marco
Alessia Peter
Barbara Guarino
Roberto Spreafico
Elisabetta Cameroni
James Brett Case
Rita E. Chen
Colin Havenar-Daughton
Gyorgy Snell
Amalio Telenti
Herbert W. Virgin
Antonio Lanzavecchia
Michael S. Diamond
Katja Fink
David Veesler
Davide Corti
[J]. Nature, 2020, 583 : 290 - 295
[2] Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
Anderson, Danielle E.
Tan, Chee Wah
Chia, Wan Ni
Young, Barnaby E.
Linster, Martin
Low, JennyG H.
Tan, Yee-Joo
Chen, Mark I-C
Smith, Gavin J. D.
Leo, Yee Sin
Lye, David C.
Wang, Lin-Fa
[J]. EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 900 - 902
[3] Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
Xia, Hongjie
Yeung, Jason
Kalveram, Birte
Bills, Cody J.
Chen, John Yun-Chung
Kurhade, Chaitanya
Zou, Jing
Widen, Steven G.
Mann, Brian R.
Kondor, Rebecca
Davis, C. Todd
Zhou, Bin
Wentworth, David E.
Xie, Xuping
Shi, Pei-Yong
[J]. EMERGING MICROBES & INFECTIONS, 2023, 12 (01)
[4] Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV
Jiang, Wen
Wang, Junchao
Jiao, Shasha
Gu, Chenjian
Xu, Wei
Chen, Ben
Wang, Rongjuan
Chen, Huilin
Xie, Youhua
Wang, An
Li, Gang
Zeng, Dadi
Zhang, Jinchao
Zhang, Min
Wang, Shuang
Wang, Mingzhu
Gui, Xun
[J]. MABS, 2021, 13 (01)
[5] Sero-epidemiological investigation and cross-neutralization activity against SARS-CoV-2 variants in cats and dogs, Thailand
Suwanpakdee, Sarin
Ketchim, Natthaphat
Thongdee, Metawee
Chaiwattanarungruengpaisan, Somjit
Tangsudjai, Siriporn
Wiriyarat, Witthawat
Julapanthong, Pruksa
Trakoolchaisri, Wachira
Buamas, Supakit
Sakcamduang, Walasinee
Okada, Pilailuk Akkapaiboon
Puthavathana, Pilaipan
Paungpin, Weena
[J]. FRONTIERS IN VETERINARY SCIENCE, 2024, 11
[6] B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Scheid, Johannes F.
Barnes, Christopher O.
Eraslan, Basak
Hudak, Andrew
Keeffe, Jennifer R.
Cosimi, Lisa A.
Brown, Eric M.
Muecksch, Frauke
Weisblum, Yiska
Zhang, Shuting
Delorey, Toni
Woolley, Ann E.
Ghantous, Fadi
Park, Sung-Moo
Phillips, Devan
Tusi, Betsabeh
Huey-Tubman, Kathryn E.
Cohen, Alexander A.
Gnanapragasam, Priyanthi N. P.
Rzasa, Kara
Hatziioanno, Theodora
Durney, Michael A.
Gu, Xiebin
Tada, Takuya
Landau, Nathaniel R.
West, Anthony P., Jr.
Rozenblatt-Rosen, Orit
Seaman, Michael S.
Baden, Lindsey R.
Graham, Daniel B.
Deguine, Jacques
Bieniasz, Paul D.
Regev, Aviv
Hung, Deborah
Bjorkman, Pamela J.
Xavier, Ramnik J.
[J]. CELL, 2021, 184 (12) : 3205 - +
[7] Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
Bates, Timothy A.
McBride, Savannah K.
Winders, Bradie
Schoen, Devin
Trautmann, Lydie
Curlin, Marcel E.
Tafesse, Fikadu G.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (02): : 179 - 181
[8] Does Cross-Neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?
Ma, Zhongren
Li, Pengfei
Ikram, Aqsa
Pan, Qiuwei
[J]. TRENDS IN IMMUNOLOGY, 2020, 41 (10) : 851 - 853
[9] Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
Liu, Hejun
Wu, Nicholas C.
Yuan, Meng
Bangaru, Sandhya
Torres, Jonathan L.
Caniels, Tom G.
van Schooten, Jelle
Zhu, Xueyong
Lee, Chang-Chun D.
Brouwer, Philip J. M.
van Gils, Marit J.
Sanders, Rogier W.
Ward, Andrew B.
Wilson, Ian A.
[J]. IMMUNITY, 2020, 53 (06) : 1272 - +
[10] RBD206-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern
Chuge Zhou
Xiaodong Zai
Ziqing Zhou
Ruihua Li
Yue Zhang
Yaohui Li
Ying Yin
Jun Zhang
Junjie Xu
Wei Chen
[J]. Signal Transduction and Targeted Therapy, 6

← 1 2 3 4 5 →